Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy

American Journal of Gastroenterology

Volumn 108, Issue 4, 2013, Pages 529-534

  Shaheen, Nicholas J ^a   Denison, Hans ^b   Björck, Karin ^b   Silberg, Debra G ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; LESOGABERAN; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESOPHAGEAL MUCOSAL BREAK; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE ENDOSCOPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL MUCOSAL DISEASE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; DRUG THERAPY, COMBINATION; ENDOSCOPY; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PHOSPHINIC ACIDS; PREVALENCE; PROPYLAMINES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84875925253     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.447     Document Type: Article

References (19)

1. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
2. Tack J. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease. Curr Opin Gastroenterol 2005; 21: 454-60.
3. Khan M, Santana J, Donnellan C et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244.
4. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis-a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24: 743-50.
5. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
6. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-30.
7. Jones R, Liker HR, DucrottéP. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007; 61: 1301-7.
8. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 334-43.
9. Shaheen NJ, Denison H, Björck K et al. Efficacy and safety of lesogaberan in gastroesophageal reflux disease: a randomized controlled trial. Gut 2012; E-pub ahead of print.
10. Vakil N, Karlsson M, Denison H et al. A patient reported outcome instrument in partial responders to proton pump inhibitor therapy suggests new symptoms deserve consideration: results of a validation study. Gut 2011; 60 (Suppl 3): A266.
11. Vakil N, Björck K, Denison H et al. Validation of the Reflux Symptom Questionnaire Electronic Diary in partial responders to proton pump inhibitor therapy. Clin Transl Gastroenterol 2012; 3: e7.
12. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
13. Malfertheiner P, Nocon M, Vieth M et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care-the ProGERD study. Aliment Pharmacol Ther 2011; 35: 154-64.
14. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-82.
15. Kahrilas PJ, Jonsson A, Denison H et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 612-9.
16. Dorval E, Rey JF, Soufflet C et al. Perspectives on gastroesophageal reflux disease in primary care: the REFLEX study of patient-physician agreement. BMC Gastroenterol 2011; 11: 25.
17. Gosselin A, Luo R, Lohoues H et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health 2009; 12: 34-9.
18. Kahrilas PJ, Shaheen NJ, Vaezi MF et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
19. Kinoshita Y, Hongo M. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol 2012; 107: 522-30.